2000 myeloma patients to help shape future cancer care
NCT ID NCT04888039
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 2000 people with multiple myeloma in the West-Occitanie region of France to see how they are treated in real life and how their quality of life changes over time. Researchers will collect data from medical records and ask patients to fill out questionnaires about their well-being. The goal is to learn what treatments work best outside of clinical trials and improve care for all patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors understand which treatments work best in everyday patients and improve quality of life for people with multiple myeloma.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data without testing new drugs, so it won't directly change care. Results may take years and might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2021
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with a diagnosis of symptomatic multiple myeloma and living in the west-Occitanie region.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient living in the West-Occitanie region * Patient with a diagnosis of symptomatic multiple myeloma (Rajkumar et al, Lancet Oncology 2014) Exclusion Criteria: * Patient opposed to this research * Patient under legal protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IUCT-Oncopole - Toulouse University Hospital
RECRUITINGToulouse, West-Occitanie, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bispecific antibody combo aims to deepen myeloma responses
- Can a stronger drug cocktail give older myeloma patients a better start?
- Cheap blood count ratios eyed as window into Myeloma's inflammatory grip
- Can a t-cell engager rescue myeloma that outsmarted CAR-T?
- Can myeloma treatment work without steroids?
- Double-Drug attack on Hard-to-Treat lymphomas